Mohammed N Tantawy1,2, H Charles Manning1,2,3,4, Todd E Peterson1,2, Daniel C Colvin1, John C Gore1,2, Wenfu Lu5, Zhenbang Chen5, C Chad Quarles6. 1. Vanderbilt University Institute of Imaging Science (VUIIS), Vanderbilt University Medical Center, 1161 21st Ave. S., AA 1105 MCN, Nashville, TN, 37232, USA. 2. Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, TN, 37232, USA. 3. Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, 37232, USA. 4. Program in Chemical and Physical Biology, Vanderbilt University Medical Center, Nashville, TN, 37232, USA. 5. Department of Biochemistry and Cancer Biology, Meharry Medical College, Nashville, TN, 37208, USA. 6. Imaging Research, Barrow Neurological Institute, 350 W Thomas Rd, Phoenix, AZ, 85013, USA. chad.quarles@barrowneuro.org.
Abstract
PURPOSE: The identification and targeting of biomarkers specific to prostate cancer (PCa) could improve its detection. Given the high expression of translocator protein (TSPO) in PCa, we investigated the use of [18F]VUIIS1008 (a novel TSPO-targeting radioligand) coupled with positron emission tomography (PET) to identify PCa in mice and to characterize their TSPO uptake. PROCEDURES: Ptenpc-/-, Trp53pc-/- prostate cancer-bearing mice (n = 9, 4-6 months old) were imaged in a 7T MRI scanner for lesion localization. Within 24 h, the mice were imaged using a microPET scanner for 60 min in dynamic mode following a retro-orbital injection of ~ 18 MBq [18F]VUIIS1008. Following imaging, tumors were harvested and stained with a TSPO antibody. Regions of interest (ROIs) were drawn around the tumor and muscle (hind limb) in the PET images. Time-activity curves (TACs) were recorded over the duration of the scan for each ROI. The mean activity concentrations between 40 and 60 min post radiotracer administration between tumor and muscle were compared. RESULTS: Tumor presence was confirmed by visual inspection of the MR images. The uptake of [18F]VUIIS1008 in the tumors was significantly higher (p < 0.05) than that in the muscle, where the percent injected dose per unit volume for tumor was 7.1 ± 1.6 % ID/ml and that of muscle was < 1 % ID/ml. In addition, positive TSPO expression was observed in tumor tissue analysis. CONCLUSIONS: The foregoing preliminary data suggest that TSPO may be a useful biomarker of PCa. Therefore, using TSPO-targeting PET ligands, such as [18F]VUIIS1008, may improve PCa detectability and characterization.
PURPOSE: The identification and targeting of biomarkers specific to prostate cancer (PCa) could improve its detection. Given the high expression of translocator protein (TSPO) in PCa, we investigated the use of [18F]VUIIS1008 (a novel TSPO-targeting radioligand) coupled with positron emission tomography (PET) to identify PCa in mice and to characterize their TSPO uptake. PROCEDURES: Ptenpc-/-, Trp53pc-/- prostate cancer-bearing mice (n = 9, 4-6 months old) were imaged in a 7T MRI scanner for lesion localization. Within 24 h, the mice were imaged using a microPET scanner for 60 min in dynamic mode following a retro-orbital injection of ~ 18 MBq [18F]VUIIS1008. Following imaging, tumors were harvested and stained with a TSPO antibody. Regions of interest (ROIs) were drawn around the tumor and muscle (hind limb) in the PET images. Time-activity curves (TACs) were recorded over the duration of the scan for each ROI. The mean activity concentrations between 40 and 60 min post radiotracer administration between tumor and muscle were compared. RESULTS:Tumor presence was confirmed by visual inspection of the MR images. The uptake of [18F]VUIIS1008 in the tumors was significantly higher (p < 0.05) than that in the muscle, where the percent injected dose per unit volume for tumor was 7.1 ± 1.6 % ID/ml and that of muscle was < 1 % ID/ml. In addition, positive TSPO expression was observed in tumor tissue analysis. CONCLUSIONS: The foregoing preliminary data suggest that TSPO may be a useful biomarker of PCa. Therefore, using TSPO-targeting PET ligands, such as [18F]VUIIS1008, may improve PCa detectability and characterization.
Entities:
Keywords:
PET; Prostate cancer; Translocator protein
Authors: A M García Vicente; A Núñez García; A M Soriano Castrejón; G A Jiménez Londoño; J M Cordero García; A Palomar Muñoz Journal: Rev Esp Med Nucl Imagen Mol Date: 2012-03-27 Impact factor: 1.359
Authors: Shelby K Wyatt; H Charles Manning; Mingfeng Bai; Moneeb Ehtesham; Khubaib Y Mapara; Reid C Thompson; Darryl J Bornhop Journal: Curr Mol Med Date: 2012-05 Impact factor: 2.222
Authors: Jason R Buck; Eliot T McKinley; Matthew R Hight; Allie Fu; Dewei Tang; Ralph Adam Smith; Mohammed Noor Tantawy; Todd E Peterson; Daniel Colvin; Mohammed Sib Ansari; Ronald M Baldwin; Ping Zhao; Saffet Guleryuz; H Charles Manning Journal: J Nucl Med Date: 2010-12-13 Impact factor: 10.057
Authors: Zhenbang Chen; Lloyd C Trotman; David Shaffer; Hui-Kuan Lin; Zohar A Dotan; Masaru Niki; Jason A Koutcher; Howard I Scher; Thomas Ludwig; William Gerald; Carlos Cordon-Cardo; Pier Paolo Pandolfi Journal: Nature Date: 2005-08-04 Impact factor: 49.962
Authors: Arlee Fafalios; Ardavan Akhavan; Anil V Parwani; Robert R Bies; Kevin J McHugh; Beth R Pflug Journal: Clin Cancer Res Date: 2009-09-29 Impact factor: 12.531
Authors: Allison S Cohen; Jun Li; Matthew R Hight; Eliot McKinley; Allie Fu; Adria Payne; Yang Liu; Dawei Zhang; Qing Xie; Mingfeng Bai; Gregory D Ayers; Mohammed Noor Tantawy; Jarrod A Smith; Frank Revetta; M Kay Washington; Chanjuan Shi; Nipun Merchant; H Charles Manning Journal: Clin Cancer Res Date: 2020-09-15 Impact factor: 12.531